Soleno Therapeutics Inc. has announced the publication of results from a pivotal clinical study evaluating VYKAT™ XR (diazoxide choline extended-release tablets) in the treatment of hyperphagia in individuals with Prader-Willi syndrome $(PWS)$. The results, now published in the Journal of Clinical Endocrinology and Metabolism, are from a 16-week randomized, double-blind, placebo-controlled withdrawal period study involving children and adults aged four years and older. The study demonstrated that participants who transitioned to placebo experienced a significant worsening of hyperphagia compared to those who remained on VYKAT XR. These findings contributed to the U.S. FDA approval of VYKAT XR as the first and only treatment for hyperphagia in PWS. The results have been publicly presented through this peer-reviewed publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9619551) on January 05, 2026, and is solely responsible for the information contained therein.